BRPI0108485B1 - derivados do antiviral azaindol - Google Patents

derivados do antiviral azaindol Download PDF

Info

Publication number
BRPI0108485B1
BRPI0108485B1 BRPI0108485A BR0108485A BRPI0108485B1 BR PI0108485 B1 BRPI0108485 B1 BR PI0108485B1 BR PI0108485 A BRPI0108485 A BR PI0108485A BR 0108485 A BR0108485 A BR 0108485A BR PI0108485 B1 BRPI0108485 B1 BR PI0108485B1
Authority
BR
Brazil
Prior art keywords
compound
piperazine
azaindol
methyl
benzoyl
Prior art date
Application number
BRPI0108485A
Other languages
English (en)
Portuguese (pt)
Other versions
BR0108485A (pt
Inventor
John A Bender
Nicholas A Meanwell
Owen B Wallace
Tao Wang
Zhongxing Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0108485(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0108485A publication Critical patent/BR0108485A/pt
Publication of BRPI0108485B1 publication Critical patent/BRPI0108485B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0108485A 2000-02-22 2001-01-19 derivados do antiviral azaindol BRPI0108485B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22
PCT/US2001/002009 WO2001062255A1 (en) 2000-02-22 2001-01-19 Antiviral azaindole derivatives

Publications (2)

Publication Number Publication Date
BR0108485A BR0108485A (pt) 2003-04-22
BRPI0108485B1 true BRPI0108485B1 (pt) 2016-08-23

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108485A BRPI0108485B1 (pt) 2000-02-22 2001-01-19 derivados do antiviral azaindol

Country Status (31)

Country Link
US (1) US20020061892A1 (enExample)
EP (1) EP1257276B1 (enExample)
JP (1) JP3868814B2 (enExample)
KR (1) KR100496574B1 (enExample)
CN (1) CN1404392A (enExample)
AR (1) AR029469A1 (enExample)
AT (1) ATE314072T1 (enExample)
AU (2) AU2001232895B2 (enExample)
BR (1) BRPI0108485B1 (enExample)
CA (1) CA2400700C (enExample)
CO (1) CO5271657A1 (enExample)
CY (1) CY1107460T1 (enExample)
DE (1) DE60116260T2 (enExample)
DK (1) DK1257276T3 (enExample)
EG (1) EG24669A (enExample)
ES (1) ES2254367T3 (enExample)
HU (1) HU229992B1 (enExample)
IL (1) IL150734A0 (enExample)
MX (1) MXPA02008113A (enExample)
MY (1) MY128458A (enExample)
NO (1) NO323564B1 (enExample)
NZ (1) NZ520317A (enExample)
PE (1) PE20020786A1 (enExample)
PL (1) PL357434A1 (enExample)
PT (1) PT1257276E (enExample)
RU (1) RU2259372C2 (enExample)
TR (1) TR200201961T2 (enExample)
TW (1) TWI293629B (enExample)
UY (1) UY26593A1 (enExample)
WO (1) WO2001062255A1 (enExample)
ZA (1) ZA200206073B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HU229305B1 (en) * 2001-02-02 2013-10-28 Bristol Myers Squibb Co Antiviral substituted azaindoleoxoacetic piperazine dervatives and compositions thereof
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
US20040162298A1 (en) * 2002-02-23 2004-08-19 Hsu-Tso Ho Method of treating HIV infection by preventing interaction of CD4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
ES2527118T3 (es) 2003-12-19 2015-01-20 Plexxikon Inc. Compuestos y procedimientos de desarrollo de moduladores de Ret
CN1953985B (zh) * 2004-03-15 2010-06-09 布里斯托尔-迈尔斯斯奎布公司 哌嗪和取代的哌啶抗病毒药物的前药
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
HRP20090034T3 (en) 2004-06-09 2009-03-31 Glaxo Group Limited Pyrrolopyridine derivatives
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
CA2629232A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101679358B (zh) * 2007-06-18 2013-10-30 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的吡咯衍生物
AU2008276063B2 (en) 2007-07-17 2013-11-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
AU2009210296B2 (en) 2008-01-31 2013-11-14 Sanofi Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals
SI2323633T1 (sl) * 2008-09-04 2012-07-31 Bristol Myers Squibb Co Stabilni farmacevtski sestavek za optimizirano razdeljevanje hiv pripetih inhibitorjev
JP5511942B2 (ja) 2009-04-03 2014-06-04 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 組成物及びその使用
EP2496086B1 (en) 2009-11-06 2017-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
SI2672967T1 (sl) 2011-02-07 2018-12-31 Plexxikon Inc. Spojine in postopki za kinazno modulacijo in indikacije zanjo
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
EP2696937B1 (en) 2011-04-12 2017-05-17 VIIV Healthcare UK (No.5) Limited Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors
EP2751119B1 (en) 2011-08-29 2016-11-23 VIIV Healthcare UK (No.5) Limited Fused bicyclic diamine derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
EP2895472B1 (en) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
CN109528749B (zh) * 2017-09-22 2023-04-28 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CN118515629A (zh) * 2020-11-24 2024-08-20 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用
CN115855899B (zh) * 2022-11-24 2025-06-10 常熟理工学院 一种荧光探针检测二氧化硫衍生物的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE142621T1 (de) * 1989-12-28 1996-09-15 Upjohn Co Diaromatische substituierte verbindungen gegen den aids-virus
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion

Also Published As

Publication number Publication date
CA2400700C (en) 2010-10-26
EP1257276A1 (en) 2002-11-20
DK1257276T3 (da) 2006-04-10
HUP0301508A2 (hu) 2003-09-29
HK1052132A1 (en) 2003-09-05
CN1404392A (zh) 2003-03-19
ATE314072T1 (de) 2006-01-15
KR20020073598A (ko) 2002-09-27
MY128458A (en) 2007-02-28
KR100496574B1 (ko) 2005-06-22
BR0108485A (pt) 2003-04-22
ES2254367T3 (es) 2006-06-16
TR200201961T2 (tr) 2002-12-23
JP2003523392A (ja) 2003-08-05
CO5271657A1 (es) 2003-04-30
EP1257276A4 (en) 2004-10-27
NZ520317A (en) 2004-05-28
WO2001062255A1 (en) 2001-08-30
NO323564B1 (no) 2007-06-11
CA2400700A1 (en) 2001-08-30
MXPA02008113A (es) 2003-01-28
PL357434A1 (en) 2004-07-26
DE60116260D1 (de) 2006-02-02
ZA200206073B (en) 2003-10-30
NO20023981D0 (no) 2002-08-21
EG24669A (en) 2010-04-11
HU229992B1 (en) 2015-04-28
JP3868814B2 (ja) 2007-01-17
UY26593A1 (es) 2001-09-28
DE60116260T2 (de) 2006-08-31
RU2259372C2 (ru) 2005-08-27
EP1257276B1 (en) 2005-12-28
AR029469A1 (es) 2003-07-02
AU3289501A (en) 2001-09-03
PE20020786A1 (es) 2002-09-06
CY1107460T1 (el) 2012-12-19
PT1257276E (pt) 2006-05-31
US20020061892A1 (en) 2002-05-23
TWI293629B (enExample) 2008-02-21
NO20023981L (no) 2002-10-17
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
RU2002125494A (ru) 2004-03-20
AU2001232895B2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
EP1257276B1 (en) Antiviral azaindole derivatives
US6476034B2 (en) Antiviral azaindole derivatives
AU2001232895A1 (en) Antiviral azaindole derivatives
ES2387981T3 (es) Composición y actividad antiviral de derivados de piperazina azaindoloxoacética sustituidos
EP2975038B1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ES2445750T3 (es) Indol, azaindol y derivados de sulfonilureidopiperazina heterocíclicos relacionados
HK1052132B (en) Antiviral azaindole derivatives
HK1202530B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK1174037B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
HK1072731B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2549 DE 12-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.